{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T04:43:00Z","timestamp":1791088980726,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd000297","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2005,4,20]],"date-time":"2005-04-20T00:00:00Z","timestamp":1113955200000}}],"reference-count":22,"publisher":"Wiley","issue":"4","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd000297.pub2","type":"journal-article","created":{"date-parts":[[2005,4,22]],"date-time":"2005-04-22T10:35:41Z","timestamp":1114166141000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Cyclosporine for induction of remission in Crohn's disease"],"prefix":"10.1002","volume":"2008","author":[{"given":"John WD","family":"McDonald","sequence":"first","affiliation":[{"name":"Robarts Research Institute; Robarts Clinical Trials; P.O. Box 5015 100 Perth Drive London Ontario Canada N6A 5K8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G","family":"Feagan","sequence":"additional","affiliation":[{"name":"Robarts Research Institute; Robarts Clinical Trials; P.O. Box 5015 100 Perth Drive London Ontario Canada N6A 5K8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek P","family":"Jewell","sequence":"additional","affiliation":[{"name":"Gibson Laboratories (2nd Floor); Gastroenterology Unit; Radcliffe Infirmary Woodstock Road OXFORD UK OX2 6HE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorn","family":"Brynskov","sequence":"additional","affiliation":[{"name":"Herlev University Hospital; Department of Medical Gastroenterology C; 75 Herlev Ringvej DK-2730 Herlev Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard F","family":"Stange","sequence":"additional","affiliation":[{"name":"Schwerpunkte Gastroenterologie, Hepatologie und Endokrinologie; Abteilung fur Innere Medizin 1; Robert Bosch Krankenhaus Postfach 501120, Auerbachstr. 110 70341 Stuttgart Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John K","family":"MacDonald","sequence":"additional","affiliation":[{"name":"Robarts Research Institute; Robarts Clinical Trials; P.O. Box 5015 100 Perth Drive London Ontario Canada N6A 5K8"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,4,20]]},"reference":[{"issue":"13","key":"10.1002\/14651858.CD000297.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1056\/NEJM198909283211301","article-title":"A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease","volume":"321","author":"Brynskov","year":"1989","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1002\/14651858.CD000297.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1056\/NEJM199406303302602","article-title":"Low-dose cyclosporine for the treatment of Crohn's disease. The Canadian Crohn's Relapse Prevention Trial Investigators","volume":"330","author":"Feagan","year":"1994","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1002\/14651858.CD000297.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/00042737-199406000-00009","article-title":"Oral cyclosporin for chronic active Crohn's disease: A multicentre controlled trial","volume":"6","author":"Jewell","year":"1994","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"3","key":"10.1002\/14651858.CD000297.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/0016-5085(95)90384-4","article-title":"European trial of cyclosporine in chronic active Crohn's disease: a 12-month study. The European Study Group","volume":"109","author":"Stange","year":"1995","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD000297.pub2-BIB0005|cit5","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003574.pub2","article-title":"Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease","author":"Akobeng","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD000297.pub2-BIB0006|cit6","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003459.pub2","article-title":"Methotrexate for induction of remission in refractory Crohn's disease","author":"Alfadhli","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8382","key":"10.1002\/14651858.CD000297.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S0140-6736(84)91358-8","article-title":"Cyclosporin for Crohn's disease","volume":"1","author":"Allison","year":"1984","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD000297.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-2036.1987.tb00604.x","article-title":"Cyclosporin for Crohn's disease","volume":"1","author":"Allison","year":"1987","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1002\/14651858.CD000297.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1365-2036.1989.tb00200.x","article-title":"Cyclosporin for the treatment of severe inflammatory bowel disease","volume":"3","author":"Baker","year":"1989","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1002\/14651858.CD000297.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1365-2036.1989.tb00199.x","article-title":"Low-dose cyclosporin for Crohn's disease: implications for clinical trials","volume":"3","author":"Brynskov","year":"1989","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10.1002\/14651858.CD000297.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"689","DOI":"10.3109\/00365529108998585","article-title":"Final report on a placebo-controlled, double-blind, randomized, multicentre trial of cyclosporin treatment in active chronic Crohn's disease","volume":"26","author":"Brynskov","year":"1991","journal-title":"Scand J Gastroenterol"},{"issue":"2","key":"10.1002\/14651858.CD000297.pub2-BIB0012|cit12","first-page":"121","article-title":"Cyclosporin treatment of anal and perianal lesions associated with Crohn's disease","volume":"14","author":"Cat","year":"2003","journal-title":"Turk J Gastroenterol"},{"issue":"16","key":"10.1002\/14651858.CD000297.pub2-BIB0013|cit13","first-page":"610","article-title":"Intravenous cyclosporine A in the treatment of refractory Crohn's disease","volume":"119","author":"Garcia-Planella","year":"2002","journal-title":"Med Clin (Barc)"},{"issue":"1","key":"10.1002\/14651858.CD000297.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa020732","article-title":"Natalizumab for active Crohn's disease","volume":"348","author":"Ghosh","year":"2003","journal-title":"New Engl J Med"},{"issue":"2","key":"10.1002\/14651858.CD000297.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1053\/gast.2001.26260","article-title":"A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease","volume":"121","author":"Gordon","year":"2001","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD000297.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/00004836-199909000-00009","article-title":"Cyclosporine therapy in inflammatory bowel disease: short-term and long-term results","volume":"29","author":"Gurudu","year":"1999","journal-title":"J Clin Gastroenterol"},{"issue":"5","key":"10.1002\/14651858.CD000297.pub2-BIB0017|cit17","first-page":"646","article-title":"Rapid closure of Crohn's disease fistulas with continuous intravenous cyclosporin A","volume":"88","author":"Hanauer","year":"1993","journal-title":"Am J Gastroenterol"},{"issue":"8167","key":"10.1002\/14651858.CD000297.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","article-title":"A simple index of Crohn's-disease activity","volume":"1","author":"Harvey","year":"1980","journal-title":"Lancet"},{"issue":"28","key":"10.1002\/14651858.CD000297.pub2-BIB0019|cit19","first-page":"2265","article-title":"High-dose intravenous cyclosporine in steroid refractory attacks of inflammatory bowel disease","volume":"46","author":"Hermida-Rodriguez","year":"1999","journal-title":"Hapatogastroenterology"},{"issue":"12","key":"10.1002\/14651858.CD000297.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/bjs.1800751213","article-title":"Treatment of Crohn's disease in relapse with cyclosporin A","volume":"75","author":"Parrott","year":"1988","journal-title":"Br J Surg"},{"issue":"3","key":"10.1002\/14651858.CD000297.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00004836-199504000-00009","article-title":"Intravenous cyclosporine for steroid-refractory attacks of Crohn's disease. Short- and long-term results","volume":"20","author":"Santos","year":"1995","journal-title":"J Clin Gastroenterol"},{"issue":"9","key":"10.1002\/14651858.CD000297.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1007\/BF01538074","article-title":"Cyclosporin A treatment in inflammatory bowel disease","volume":"34","author":"Stange","year":"1989","journal-title":"Dig Dis Sci"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD000297.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:18:56Z","timestamp":1762503536000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD000297.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane IBD Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2005,4,20]]},"references-count":22,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2008,4]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd000297.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,4,20]]}}}